SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 968.93 |
| Enterprise Value ($M) | 988.36 |
| Book Value ($M) | 98.47 |
| Book Value / Share | 1.15 |
| Price / Book | 9.84 |
| NCAV ($M) | 28.04 |
| NCAV / Share | 0.33 |
| Price / NCAV | 34.55 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.89 |
| Return on Assets (ROA) | -0.80 |
| Return on Equity (ROE) | -0.91 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.29 |
| Current Ratio | 3.72 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 54.81 |
| Assets | 125.24 |
| Liabilities | 26.77 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D | Ma Songjiang | 7.62 | ||
| 13D | Luo Ying | 8.54 | ||
| 13G/A | Lytton Laurence W | 0.00 | ||
| 13D/A | GNI Group Ltd. | 85.34 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 16,349 | 55,803 | 29.30 | |
| 21,498 | 93,516 | 22.99 | |
| 34,453 | 83,790 | 41.12 | |
| 13,037 | 31,509 | 41.38 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GOVX – GeoVax Labs, Inc. | GRCE – Grace Therapeutics, Inc. |
| GTBP – GT Biopharma, Inc. | HEPA – Hepion Pharmaceuticals, Inc. |
| HOOK – HOOKIPA Pharma Inc. |
Financial data and stock pages provided by
Fintel.io